Search PubMed⌕ Search

Biomedical subjects

A D Allen

Publications and source records attributed to A D Allen.

49 records · Page 3Linked to original sources

Effects of estradiol on platelet aggregation in mouse mesenteric arterioles and ex vivo.

Mice were implanted subcutaneously with a pellet containing 0.5 mg estradiol or with a placebo. Eight to 12 days later platelet aggregation was produced in mesenteric arterioles by injuring their endothelium in vivo with a noxious light/dye stimulus. The time between the onset of the noxious stimulus and the appearance of platelet aggregates was significantly shortened (p less than .01) in the estradiol treated mice. In contrast to this enhancement of aggregation, when platelets were tested ex vivo in platelet rich plasma (PRP), aggregation to sodium arachidonate was inhibited in estradiol treated mice. Aggregation of PRP by ADP was not affected by estradiol treatment of the mice. Thus the enhanced aggregation observed in injured mesenteric arterioles of estradiol treated mice may not reflect direct effects of estradiol on the platelet itself. Rather enhanced aggregation may reflect an effect of estradiol on endothelium or adjacent tissue. The data are discussed in light of other literature concerning estradiol effects in rodents, and in light of literature suggesting that an increased number of thromboembolic events occurs in humans receiving high doses of estrogens.

Adenosine Diphosphate↗

Simple medium for the selective isolation of Bacteroides and related organisms, and their occurrence in sewage.

A medium composed of 0.009% sodium azide, 0.07% sodium deoxycholate, and 0.0007% ethyl violet in Brain Heart Infusion Agar (Difco) and a process of incubation in an atmosphere of 90% N(2) and 10% CO(2) for the selective isolation of certain members of the intestinal bacteroides are described. The medium appears to select predominantly members of the genus Bacteroides and a few of the genus Sphaerophorus. A survey of the occurrence of these organisms in sewage and various stages of sewage treatment indicates that they survive complete sewage treatment in low numbers and that their rate of decline parallels that of the coliforms. Large numbers were recovered from sludge digestion tanks, suggesting a possible role in the anaerobic breakdown of organic matter.

Bacteroides↗

Effects of estradiol on platelet aggregation in cerebral microvessels of mice.

Mice were implanted subcutaneously with a pellet containing 0.5 mg estradiol or with a placebo. Eight to 12 days later platelet aggregation was produced in pial arterioles by injuring their endothelium in vivo with a noxious light/dye stimulus. The time between the onset of the noxious stimulus and the appearance of platelet aggregates was significantly shortened (p less than .02) by estradiol treatment in young (2 month old) mice. The same treatment had the opposite effect in 4-6 month old mice and significantly delayed the onset of aggregation (p = .01). When platelet rich plasma (PRP) was prepared, aggregation by sodium arachidonate was always inhibited in PRP from estradiol treated mice, irrespective of age. Estradiol treatment had no effect on aggregation induced ex vivo by ADP. Thus the enhanced aggregation observed in pial arterioles of young estradiol treated mice may not reflect direct effects of estradiol on the platelet itself. The data are discussed in light of the literature suggesting enhancement of ischemic vascular disease, including strokes, in patients receiving estrogens, and especially high doses of estrogens.

Adenosine Diphosphate↗

Making moral decisions on a double-blinded drug trial in progress without breaking the code: a primer on posterior analysis.

The double blinding of drug trials to prevent bias deprives physicians of information they need in order to comply with their duty to treat patients and do them no harm. This ethical dilemma can be ameliorated with a standard statistical method known as posterior analysis. The clinical researcher can use posterior analysis to calculate the probability that a patient in a double-blinded drug trial is in the placebo group, based on the patient's clinical status. The clinician can also calculate the probability that the drug is safe and efficacious, as compared with the placebo, without breaking the code.

Clinical Trials as Topic↗